Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b.
J Neurol
; 251(12): 1498-501, 2004 Dec.
Article
en En
| MEDLINE
| ID: mdl-15645350
ABSTRACT
We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), synapsin and S-100B. Before treatment, one patient had elevated TPO antibodies, four patients had elevated antibodies against S-100B, two patients against MOG or synapsin and one patient against MBP. In two patients we observed a continuous increase of dsDNA or TPO antibodies above the normal range. This rise paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Autoanticuerpos
/
Adyuvantes Inmunológicos
/
Interferón beta
/
Esclerosis Múltiple Crónica Progresiva
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Neurol
Año:
2004
Tipo del documento:
Article
País de afiliación:
Alemania